Regulation

The HHS policy,
explained.

On 28 October 2026 HHS said it would not act against licensed compounders making six unapproved peptides, under ten conditions. Here is what that covers, and what it doesn't.

Short answerRegulation · 7 min read · Updated 17 Nov 2026

It is an interim, non-binding enforcement-discretion policy. HHS says it will not take action against state-licensed pharmacies, federal facilities or licensed physicians compounding BPC-157, Epitalon, KPV, MOTS-c, Semax or TB-500, if ten conditions are met. It does not approve any of them, does not add them to the 503A bulks list, and says nothing that makes research-chemical sales for human use lawful.

01What happened, in order

DateEventWhat it changed
2023FDA places many popular peptides in Category 2 of its interim 503A listCompounding them became off-limits
15–22 Apr 2026Twelve peptides leave Category 2 after nominations are withdrawnRemoval alone did not make them compoundable
23–24 Jul 2026FDA's Pharmacy Compounding Advisory Committee narrowly backs six of seven peptides for the bulks listAdvisory only; FDA career staff had opposed
28 Oct 2026HHS files the enforcement-discretion policyLicensed compounders may proceed under ten conditions
30 Oct 2026Published in the Federal Register; two-week comment windowComments closed around 13 November
NextFDA notice-and-comment rulemaking on the bulks listThe only route to a permanent listing; can take months to years

02The six peptides covered

BPC-157

Covered with a defined identity and limited route, set out in the policy's appendix.

TB-500

Covered. Not the same molecule as full-length thymosin β4.

KPV

Covered. The tripeptide fragment of α-MSH.

MOTS-c

Covered. A mitochondria-derived peptide.

Semax

Covered. A synthetic ACTH(4–10) analogue.

Epitalon

Covered. A synthetic tetrapeptide.

03The ten conditions

All ten must be met for the policy to apply. Paraphrased from the published summary.

1
One of the six

The substance must be listed in the policy's appendix.

2
Identity and route match

Same identity and limited route of administration as the appendix specifies.

3
Registered source with a COA

Bulk substance from an FDA-registered facility, with a valid certificate of analysis.

4
CGMP manufacturer

The original bulk manufacturer is FDA-registered and CGMP-compliant.

5
Adverse-event reporting

Serious adverse events are reported to FDA MedWatch.

6
Fixed label statement

“This is a compounded drug product. Not for resale.”

7
Single active ingredient

No blends or combination products.

8
Oral bioavailability evidence

Oral products need documentation that the formulation is adequately bioavailable.

9
Device limits

The only device packaged with the product is an FDA 510(k)-cleared syringe.

10
Everything else still applies

All other FD&C Act requirements remain in force.

04What it does not do

  • It does not approve any peptide or make any safety or efficacy finding.
  • It does not add anything to the 503A bulks list; only rulemaking can.
  • It does not cover blends, “stacks” or multi-ingredient products.
  • It says nothing that makes selling research chemicals for human use lawful.
  • It does not change anti-doping rules: sport bodies apply their own list.
  • It is interim and non-binding, and HHS says it may revisit it if a safety or quality signal appears.

05What it means for research-use supply

Very little, directly. The policy is about prescription compounding by licensed pharmacies and physicians in the United States. Research-use-only supply is a separate lane with separate rules, and those rules depend on how a product is presented and to whom it is sold.

One indirect effect is worth noting: the policy sets a documentation bar (registered source, valid COA, CGMP manufacturer, single ingredient) that buyers in every lane will start to expect. We publish a certificate for every batch for the same reason.

RefSources

  1. Federal Register (public inspection). Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, 2026-22192. Filed 28 October 2026. public-inspection.federalregister.gov/2026-22192.pdf
  2. Foley & Lardner. Peptides: HHS Announces Limited Enforcement Discretion for Compounding of Six Peptides. 30 October 2026. www.foley.com/?p=130749
  3. AJMC. HHS Draft Policy Eases Enforcement on 6 Compounded Peptides. 29 October 2026. www.ajmc.com/view/hhs-draft-policy-eases-enforcement-on-6-c…
  4. Becker's Hospital Review. HHS allows compounding of 6 unapproved peptides. October 2026. www.beckershospitalreview.com/glp-1s/hhs-allows-compounding…
  5. Akin Gump. HHS Announces Interim Enforcement Discretion Policy for Compounding Six Peptides. 10 November 2026. www.akingump.com/en/insights/blogs/eye-on-fda/hhs-announces…
  6. National Law Review. FDA Committee Supports Peptide Compounding: What Comes Next. July 2026. natlawreview.com/article/fda-committee-supports-peptide-com…
  7. Frier Levitt. FDA to Remove 12 Popular Peptides from the Category 2 “Do Not Compound” List. April 2026. www.frierlevitt.com/articles/fda-peptides-do-not-compound-l…

Plain-English summary of public sources, not legal or medical advice. Last checked 17 Nov 2026.

Questions

Is BPC-157 legal now?

Not in the sense most people mean. Under the interim policy, licensed US compounders can prepare it on prescription if ten conditions are met. It is still not an approved drug in any country, and it is still prohibited in sport.

Is this FDA approval?

No. It is an enforcement-discretion policy issued by HHS. Approval requires a new drug application, which none of the six has.

How long does it last?

Until each peptide is addressed in a final rule, unless HHS revisits it earlier.

Does it apply outside the US?

No. In the EU and UK, medicines law is separate and generally stricter. See our country guide.

Evidence before hype.

One email a week: new research explained and regulatory changes. No prices, no hype.

Get the 6:00 brief

Free. Unsubscribe any time.

Written by 6AM Research. Drafted from primary sources; every claim links to its source, and the page is dated. Editorial policy · How we check every page
Every batch has a public lab report. Look it up by the batch number on the vial. Batch COA lookup